ArticleDrug delivery and translational research2026
Immunotherapeutic efficacy of transdermal delivery of anti-CD3 antibody-conjugated magnetic nanoparticles using a hyaluronic acid-based dissolving microneedle patch.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Transdermal delivery of biologics remains challenging due to the stratum corneum barrier, which limits the clinical translation of antibody-based immunotherapies. In this proof-of-concept study, we developed a biodegradable hyaluronic acid (HA)-based dissolving microneedle (MN) patch incorporating anti-CD3 monoclonal antibody-conjugated magnetic nanoparticles (Ab-MNPs) as a minimally invasive transdermal immunomodulatory platform. Anti-CD3 antibodies were covalently conjugated to dextran-coated, amine-functionalized Fe₃O₄ nanoparticles using glutaraldehyde chemistry and subsequently incorporated into HA microneedles by mold replication. The fabricated MN arrays exhibited uniform morphology with well-defined needle structures and retained the magnetic responsiveness of the incorporated nanoparticles after fabrication. Therapeutic feasibility was evaluated in a concanavalin A (ConA)-induced inflammatory mouse model. Animals received one, two, or three identical MN patches before ConA challenge, followed by measurement of serum interleukin-6 (IL-6) and interferon-gamma (IFN-γ). Compared with the untreated inflammatory control, MN-treated groups showed reduced circulating IL-6 and IFN-γ concentrations, with a general patch-number-associated trend toward greater cytokine reduction. Because antibody loading, delivered dose, pharmacokinetics, biodistribution, and local release kinetics were not quantified, these findings should be interpreted as preliminary evidence of biological activity rather than confirmation of a quantitative dose-response relationship or CD3-specific immunomodulatory mechanism. Overall, this study demonstrates the feasibility of integrating antibody-conjugated magnetic nanoparticles into a biodegradable HA microneedle platform for minimally invasive transdermal delivery and provides a foundation for future investigations incorporating quantitative drug delivery analysis, mechanistic immunological evaluation, pharmacokinetic characterization, biodistribution studies, and comprehensive safety assessment to facilitate translational development.
Indexed as
Identifiers
42629544What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.